PMID- 30248571
OWN - NLM
STAT- In-Data-Review
LR  - 20181006
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 394
DP  - 2018 Nov 15
TI  - Long-term follow-up for multiple sclerosis patients initially treated with
      interferon-beta and glatiramer acetate.
PG  - 127-131
LID - S0022-510X(18)30382-4 [pii]
LID - 10.1016/j.jns.2018.09.020 [doi]
AB  - OBJECTIVE: Our goal was to compare subjects treated with glatiramer acetate (GA) 
      and interferon-beta (IFN-beta) in terms of long-term clinical outcomes. METHODS: 
      Subjects enrolled in the CLIMB who initiated either GA or IFN-beta within five
      years of disease onset and prior to 2008 were identified (n=150 for GA and n=144 
      for IFN-beta). The two treatment groups were compared in terms of long-term
      clinical outcomes: time to EDSS 4, time to EDSS 6 and EDSS score seven years
      after treatment initiation. Baseline confounders included in our analysis were
      age, gender, disease duration, attacks in the previous year, EDSS prior to
      treatment initiation, and year of treatment initiation. The groups were compared 
      using three approaches to handle confounders: multiple regression adjusting for
      confounders, adjustment for the propensity score, and inverse probability of
      treatment weighting. In addition, we assessed potential predictors of
      differential treatment response using multiple regression models including
      appropriate interaction terms. RESULTS: Subjects initially treated with GA had a 
      slightly higher hazard of reaching EDSS 4 and EDSS 6, but the difference between 
      the groups was not statistically significant (adjusted HR for EDSS 4=1.48; 95%
      CI: 0.77,2.84; p=.24; adjusted HR for EDSS 6=1.46; 95% CI: 0.70,3.05; p=.316).
      For the EDSS score at year 7, there was also only a small difference between the 
      groups. Subjects treated with GA had a longer time until treatment cessation
      (adjusted HR=0.70; 95% CI: 0.53,0.93; p=.012). The interaction models did not
      show strong evidence for the baseline predictors being associated with treatment 
      response. CONCLUSIONS: Subjects treated with glatiramer acetate and
      interferon-beta had similar long-term clinical course.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Healy, Brian C
AU  - Healy BC
AD  - Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA,
      USA; Department of Neurology, Harvard Medical School, Boston, MA, USA;
      Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA. Electronic
      address: bchealy@partners.org.
FAU - Glanz, Bonnie I
AU  - Glanz BI
AD  - Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA,
      USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
FAU - Zurawski, Jonathan D
AU  - Zurawski JD
AD  - Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA,
      USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
FAU - Mazzola, Maria
AU  - Mazzola M
AD  - Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA,
      USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
FAU - Chitnis, Tanuja
AU  - Chitnis T
AD  - Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA,
      USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
FAU - Weiner, Howard L
AU  - Weiner HL
AD  - Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA,
      USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20180917
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
OTO - NOTNLM
OT  - Long term outcomes
OT  - Multiple sclerosis
OT  - Treatment
EDAT- 2018/09/25 06:00
MHDA- 2018/09/25 06:00
CRDT- 2018/09/25 06:00
PHST- 2018/04/26 00:00 [received]
PHST- 2018/09/06 00:00 [revised]
PHST- 2018/09/14 00:00 [accepted]
PHST- 2018/09/25 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2018/09/25 06:00 [entrez]
AID - S0022-510X(18)30382-4 [pii]
AID - 10.1016/j.jns.2018.09.020 [doi]
PST - ppublish
SO  - J Neurol Sci. 2018 Nov 15;394:127-131. doi: 10.1016/j.jns.2018.09.020. Epub 2018 
      Sep 17.